Suppr超能文献

结直肠癌肝转移患者肝移植与肝切除的比较:根据肿瘤负荷评分分层的患者生存获益分析

Liver transplantation versus liver resection for colorectal liver metastasis: a survival benefit analysis in patients stratified according to tumor burden score.

作者信息

Lanari Jacopo, Hagness Morten, Sartori Alessandra, Rosso Eugenia, Gringeri Enrico, Dueland Svein, Cillo Umberto, Line Pål-Dag

机构信息

Department of Surgery, Oncology and Gastroenterology (DiSCOG), Hepatobiliary Surgery and Liver Transplantation Unit, Padua University Hospital, Padua, Italy.

Department of Transplantation Medicine, Oslo universitetssykehus Rikshospitalet, Oslo, Norway.

出版信息

Transpl Int. 2021 Sep;34(9):1722-1732. doi: 10.1111/tri.13981.

Abstract

Liver transplantation (LT) for colorectal liver metastasis (CRLM) may provide excellent survival rates in patients with unresectable disease. High tumor load is a risk factor for recurrence and low overall survival (OS) after liver resection (LR). We tested the hypothesis that LT could offer better survival than LR in patients with high tumor load. LR performed at Padua University Hospital for CRLM was compared with LT for unresectable CRLM performed both at Oslo and Padua. High tumor load was defined as tumor burden score (TBS) ≥ 9, and inclusion criteria were as in the SECA-I transplant study. 184 patients were eligible: 128 LRs and 56 LTs. 5-year OS after LR and LT was 40.5% and 54.7% (P = 0.102). In the high TBS cohort, 5-year OS after LR and LT was 22.7% and 52.2% (P = 0.055). In patients with Oslo score ≤ 2 and TBS ≥ 9 (13 LR; 24 LT) the 5-year OS after LR and LT was 14.6% and 69.1% (P = 0.002). The corresponding disease-free survival (DFS) was 0% and 22.9% (P = 0.005). Selected CRLM patients with low Oslo score and high TBS could benefit from LT with survival outcomes that are far better than what is achieved by LR.

摘要

对于不可切除的结直肠癌肝转移(CRLM)患者,肝移植(LT)可能带来出色的生存率。高肿瘤负荷是肝切除(LR)后复发和总生存期(OS)较低的一个危险因素。我们检验了这样一个假设:对于高肿瘤负荷的患者,LT能比LR提供更好的生存期。将帕多瓦大学医院针对CRLM进行的LR与奥斯陆和帕多瓦针对不可切除CRLM进行的LT进行比较。高肿瘤负荷定义为肿瘤负荷评分(TBS)≥9,纳入标准与SECA-I移植研究相同。184例患者符合条件:128例行LR,56例行LT。LR和LT后的5年总生存率分别为40.5%和54.7%(P = 0.102)。在高TBS队列中,LR和LT后的5年总生存率分别为22.7%和52.2%(P = 0.055)。在奥斯陆评分≤2且TBS≥9的患者中(13例行LR;24例行LT),LR和LT后的5年总生存率分别为14.6%和69.1%(P = 0.002)。相应的无病生存率(DFS)分别为0%和22.9%(P = 0.005)。部分奥斯陆评分低且TBS高的CRLM患者可从LT中获益,其生存结果远优于LR。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验